Cytokinetics & Amgen: positive heart failure drug without side effects? (CYTK, AMGN)
Cytokinetics Inc. (NASDAQ: CYTK) has presented data showing that its late trials of its CK-1827452 at the 2008 Heart Failure Congress of the European Society of Cardiology, which is being developed along with Amgen Inc. (NASDAQ: AMGN).
The company announced positive results from an interim analysis of an ongoing Phase IIa clinical trial evaluating CK-1827452 intravenously administered to patients with stable heart failure. The highlighted data is from an interim analysis of an ongoing Phase IIa clinical trial designed to evaluate CK-1827452 in patients with stable heart failure.
At the time of the analysis, 22 patients were evaluated and the safety data from this analysis suggest that CK-1827452 is well-tolerated with no serious adverse events reported in heart failure patients exposed to the intended range of doses and plasma concentrations.
We have yet to see any serious movement in this stock yet, but the critical part on top of results here is “no serious adverse events” as so many heart failure drugs and other heart medications have often severe side effects.
As this data is being presented at a conference, some of it may have already been known or already been hinted at. We have seen no activity in CYTK’s stock this morning as of yet even though indications are higher and it only trades 155,000 shares per day.
Jon Ogg
June 16, 2008